May 16, 2017
1 pm to 2 pm EDT

Sponsored by

Webinar Description:

Protein phosphorylation is one of the primary post-translational mechanisms by which proteins that control cancer cell proliferation and survival are regulated. This symposium will provide an overview of our new flow cytometry-based capabilities to monitor target signaling protein phosphorylation in combination with immunophenotypic analysis at a single cell level in both cancerous and immune cells. The course will include monitoring changes in the phosphorylation state of relevant oncogenic target pathways for proliferation (e.g., MEK and ERK) and survival (e.g., AKT and S6K) in cancer cells. Further, we will demonstrate immune cell profiling of pSTAT5 in T cells. These assays enable our clients’ research of novel kinase inhibitors or pathways that modulate kinase targets in complex mixtures of tumor cells and immune cells.

Learning Objectives:

• Flow cytometry of phospho-kinase targets in cancer cells
• Flow methods to link phosphoprotein regulation and the induction of apoptosis
• How phospho-flow analysis of protein phosphorylation can be used to test target cancer cell sensitivity to new drugs using the following systems:
• RAF/MEK/ERK pathway
• PI3K/AKT/mTOR pathway
• Demonstrate that immunophenotyping can combine with phospho-flow to analyze STAT5 signaling in immune subsets within a heterogeneous population

Speakers:

Dylan Daniel, Ph.D.

Director, Scientific Development

MI Bioresearch

Dr. Dylan Daniel, is an immunologist and preclinical oncology pharmacologist with leadership experience in all phases of early R&D for oncology and cancer immunotherapy. Dr. Daniel has a Ph.D. in Microbiology and Immunology and conducted post-doctoral work with Doug Hanahan at UCSF where he worked on immuno-oncology in genetically engineered mouse models. From there, Dr. Daniel worked at Genentech and then Novartis. In both companies he was focused on oncology pharmacology with small molecule and biologic drug discovery and development. Just previous to joining MI Bioresearch, Dr. Daniel was Chief Science Officer and Co-Founder of Patronus Therapeutics, Inc., a small biotechnology start-up developing novel oncology therapeutics.

David Draper, Ph.D.

Scientist, In Vitro Operations

MI Bioresearch

Dr. David Draper is an immunologist and senior member of the Flow Cytometry Team at MI Bioresearch. Dr. Draper holds a Ph.D. in Microbiology from North Carolina State University. His post-doctoral work at Duke University and the National Institutes of Health focused on uncovering the mechanisms of the host pulmonary immune response to bacterial, viral, and allergen challenge using genetically engineered animal models. This body of work provided the foundation of Dr. Draper’s technical expertise in the area of immune cell immunophenotypic and functional characterization. Dr. Draper has also held immunodiagnostic and R&D positions within the Clinical Immunology/Flow Cytometry department at the Carolinas Medical Center and BD Biosciences prior to joining MI Bioresearch in 2015.